Insulin resistance and the endothelium
Authors:
- Manuel J. QuiñonesMQManuel J. Quiñones
- Susanne B. NicholasSNSusanne B. Nicholas
- Christopher J. LyonCLChristopher J. Lyon
- 1 July 2005
- journal article
- review article
- Published by Springer Nature in Current Diabetes Reports
- Vol. 5 (4) , 246-253
Abstract
Type 2 diabetes is a cardiovascular disease equivalent that is associated with accelerated atherosclerosis and significant mortality. However, the metabolic syndrome and prediabetes are associated with increased cardiovascular mortality, indicating that atherogenic vascular changes begin prior to the onset of overt diabetes. At the core of diabetes and the metabolic syndrome is insulin resistance (IR), which sets the stage for dyslipidemia, hypertension, and inflammation. Endothelial dysfunction is the first stage of the atherosclerosis process and results from exposure to cardiovascular risk factors, such as IR and diabetes. IR and atherosclerosis follow parallel paths as they progress in severity. Thiazolidinediones, angiotensin-converting enzyme inhibitors, angiotensin receptor-AT1 blockers, and statins are widely used in the treatment of diabetes. Emerging evidence indicates that these pharmacologic agents have added mechanisms of action, especially on the endothelium and in the prevention of diabetes.Keywords
This publication has 68 references indexed in Scilit:
- Coronary Circulatory Dysfunction in Insulin Resistance, Impaired Glucose Tolerance, and Type 2 Diabetes MellitusCirculation, 2005
- Renin-angiotensin system inhibition prevents type 2 diabetes mellitusDiabetes & Metabolism, 2004
- C-Reactive Protein: Risk Marker or Mediator in Atherothrombosis?Hypertension, 2004
- Beyond the LaboratoryCirculation, 2004
- Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist With Selective PPARγ–Modulating ActivityHypertension, 2004
- Impaired myocardial vasodilatation during hyperaemic stress is improved by simvastatin but not by pravastatin in patients with hypercholesterolaemiaEuropean Heart Journal, 2004
- Preventing Type II Diabetes MellitusThe Journal of Clinical Pharmacology, 2004
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Is glucose a continuous risk factor for cardiovascular mortality?Diabetes Care, 1999
- Losartan but Not Verapamil Inhibits Angiotensin II–Induced Tissue Endothelin-1 IncreaseHypertension, 1998